Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

ThromboGenics submits BLA for ocriplasmin

Dec. 28, 2011

No Comments

Enrollment begins in phase III trial of CF-101

Dec. 27, 2011

No Comments

Novel lysophospholipid S1P1 receptor modulators characterized at Allergan

Dec. 12, 2011

No Comments

Bayer and Regeneron report integrated analysis of VIEW studies

Dec. 5, 2011

No Comments

Kowa begins long-term phase III trial of potential glaucoma treatment in Japan

Dec. 1, 2011

No Comments

Omeros submits pediatric investigation plan to EMA for OMS-302

Nov. 30, 2011

No Comments

Proximagen and Altacor enter agreement for serotonin 5-HT2C program

Nov. 30, 2011

No Comments

Akebia begins dosing in first-in-man phase I AKB-9778 study

Nov. 29, 2011

No Comments

Regeneron and Bayer commence Chinese phase III study of Eylea

Nov. 28, 2011

No Comments

Bausch & Lomb completes patient recruitment in BOL-303259-X study

Nov. 28, 2011

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

ThromboGenics submits BLA for ocriplasmin

Enrollment begins in phase III trial of CF-101

Novel lysophospholipid S1P1 receptor modulators characterized at Allergan

Bayer and Regeneron report integrated analysis of VIEW studies

Kowa begins long-term phase III trial of potential glaucoma treatment in Japan

Omeros submits pediatric investigation plan to EMA for OMS-302

Proximagen and Altacor enter agreement for serotonin 5-HT2C program

Akebia begins dosing in first-in-man phase I AKB-9778 study

Regeneron and Bayer commence Chinese phase III study of Eylea

Bausch & Lomb completes patient recruitment in BOL-303259-X study

Today's news in brief

Today's news in brief

Enhanced Cognition: Lewy body dementia phase II pumps stock

Second insulin receptor offers new therapeutic avenues

Experimental mRNA gene therapy suppresses preeclampsia in mice

Ocular RSS

Ocular
RSS